If given the green light by the FDA, a CAR T cell therapy from Kyverna Therapeutics would be the first approved treatment for stiff person syndrome.
This ‘living drug’ could change the course of autoimmune disease
If given the green light by the FDA, a CAR T cell therapy from Kyverna Therapeutics would be the first approved treatment for stiff person syndrome.